Indications
| Indication Category | Clinical Context |
|---|---|
| Primary bone tumor | Diagnosis and grading of lesions with nonspecific or aggressive imaging features; must be coordinated with orthopedic oncology before biopsy to plan tract within surgical excision field |
| Bone metastasis | Confirmation or exclusion of bone metastasis in known primary malignancy; molecular receptor and biomarker characterization for personalized therapy |
| Unknown primary | Osseous lesion without identified primary; tissue characterization to direct systemic workup and treatment |
| Pathologic fracture | Determination of benign vs. malignant etiology, particularly for vertebral compression fractures with equivocal imaging |
| Osteomyelitis / spondylodiscitis | Confirmation and microbiological culture/sensitivity for targeted antibiotic therapy; CT guidance preferred to ensure sample from bone rather than adjacent soft tissue |
| Treatment response / recurrence | Quantification of treatment response; post-treatment change vs. recurrent tumor |
Contraindications
| Type | Contraindication |
|---|---|
| Absolute | Active infection along planned biopsy route (overlying skin/soft tissue infection contaminating target); incomplete pre-biopsy imaging; no safe biopsy path; uncorrectable coagulopathy; for sarcoma: incomplete information regarding surgical excision route when limb-salvage surgery is planned |
| Relative | Coagulopathy requiring correction; pregnancy (multidisciplinary discussion; delay post-partum if possible); highly vascular spinal tumors (consider pre-embolization); hemodynamic instability |
Critical — Primary bone sarcoma: Mandatory pre-procedure consultation with orthopedic oncology for any suspected primary bone sarcoma. The biopsy tract will be excised en bloc with the tumor at surgery — an improperly placed tract that crosses compartments, joint spaces, or neurovascular structures may eliminate the possibility of limb-salvage surgery.
Relevant Anatomy
Target Selection Principles
CT provides definitive visualization of osseous anatomy, cortical integrity, medullary involvement, and adjacent compartment boundaries — the preferred guidance modality for most bone biopsies. Target viable, metabolically active tissue rather than necrotic or treated areas. For large lesions, target the periphery of the lesion at the tumor-normal interface. PET/CT co-registration is the most reliable method to identify high-yield targets in heterogeneous or post-treatment lesions.
For lytic lesions with a soft tissue component, approach through bone into the soft tissue component — yields higher diagnostic cellularity. For sclerotic lesions (dense bone), a powered drill technique is required; plan the approach through the thinnest cortical region available. For vertebral lesions, the transpedicular approach is standard — it provides direct access to the vertebral body while avoiding the disc space and spinal canal.
Danger Structures by Region
For long bone lesions, identify and avoid neurovascular bundles in the adjacent soft tissue — review MRI for exact relationships. For thoracic spine and rib biopsies, the pleura is at risk — plan below the rib margin and confirm approach angle avoids the pleural space. For pelvic lesions, major iliac vessels require CT-based trajectory planning. For all extremity lesions in cases of suspected primary sarcoma, the needle tract must never cross joint spaces or contaminate uninvolved compartments.
Pre-Procedure Checklist
Imaging Review
- Radiographs: assess matrix (osteoid, chondroid, fibrous), margins, periosteal reaction — identify "do not touch" lesions (bone island, non-ossifying fibroma, enchondroma) that do not require biopsy
- CT: cortical anatomy, medullary involvement, compartment assessment
- MRI: bone marrow and soft tissue extension, joint involvement, neurovascular relationships
- PET/CT: viable vs. necrotic tissue; high-yield target identification for heterogeneous lesions
Labs and Patient Assessment
- Coagulation studies (INR, aPTT) and platelet count; correct coagulopathy before proceeding
- Antibiotic prophylaxis not routine; administer when clinically indicated (suspected infection, immunocompromised patient)
- Anesthesiology consultation for high ASA status or complex airway
Pathology Coordination
Contact pathology in advance to confirm container requirements — formalin for routine histology; saline or RPMI for lymphoma (flow cytometry requires viable cells); saline for culture if infection is suspected. Confirm number of cores required and whether on-site adequacy assessment is available.
Consent Considerations
Discuss: non-diagnostic sample (up to 10–20% depending on lesion characteristics), infection, hemorrhage, fracture (particularly for lytic or sclerotic lesions), injury to adjacent neurovascular structures, tumor seeding along the biopsy tract (reason the tract must be within the surgical excision field for primary sarcomas).
Procedure Overview
The following is a high-level summary. Full step-by-step technique, equipment selection, and troubleshooting are available in RadCall Pro.
- Planning CT — review all prior imaging; plan trajectory to target viable tissue; confirm approach is within the planned surgical field for suspected primary sarcomas; select approach to avoid neurovascular structures, pleura, and joint spaces
- Patient positioning and setup — position to minimize distance from skin to target; sterile prep and drape; confirm time-out with target site and laterality
- Local anesthesia — generous infiltration from skin through soft tissue to periosteum; periosteal anesthesia is critical as this is the primary source of procedure pain; allow adequate dwell time before drilling
- Cortical access — for sclerotic or intact cortex, a powered drill or manual trephine is required to create the cortical window; for lytic lesions with cortical breakthrough, soft tissue component may be accessible with a standard core biopsy needle through a smaller cortical opening
- Sampling — obtain multiple core specimens from the target zone; for large heterogeneous lesions, sample from the PET-avid region; for lytic lesions, sample the soft tissue component and the bone-tumor interface
- Specimen collection — distribute specimens to appropriate containers per pre-procedure pathology coordination; label each container immediately
- Post-procedure CT — assess for complications (hemorrhage, pneumothorax for thoracic biopsies, fracture) before moving the patient
Complications
| Complication | Rate | Recognition & Management |
|---|---|---|
| Non-diagnostic sample | 5–20% depending on lesion type | Higher rates with sclerotic lesions, treated tumors, and necrotic targets; repeat biopsy targeting viable tissue; consider open surgical biopsy for critical cases |
| Hemorrhage | ~1–3% | Soft tissue hematoma most common; significant bleeding rare; pre-embolization for highly vascular tumors; embolization for active arterial bleeding |
| Infection | <1% | Higher risk with immunocompromised patients; standard sterile technique; prophylactic antibiotics when indicated |
| Pathologic fracture | Rare | Higher risk with lytic cortical lesions; orthopedic consultation for unstable fractures; prophylactic fixation may be appropriate pre-biopsy for lesions at high fracture risk |
| Tumor seeding along tract | Rare; consequential for sarcoma | Most important for primary bone sarcomas — an improperly placed tract that is not excised at surgery can cause local recurrence; prevented by pre-procedure orthopedic oncology consultation |
| Pneumothorax | Rare (thoracic spine/rib) | Thoracic approach risk; small — observation; significant — chest tube |
Post-Procedure Care
Monitoring
- 1–2 hours observation post-procedure; vital signs every 30 minutes
- Post-procedure CT to assess for hemorrhage and fracture before mobilization
- For thoracic biopsies: chest X-ray at 2 hours to assess for pneumothorax
- Pain assessment — analgesics as needed; periosteal pain is expected and typically resolves within 24–48 hours
Follow-up
- Pathology results reviewed at multidisciplinary tumor board when available — critical for primary bone tumor management
- Molecular profiling results may take 1–2 additional weeks; coordinate with oncology team
- For osteomyelitis: culture and sensitivity results guide antibiotic choice; infectious disease consultation
When to Escalate
- Suspected primary bone sarcoma not yet discussed with orthopedic oncology — do not proceed; obtain orthopedic oncology consultation first to plan biopsy tract within the surgical excision field
- Non-diagnostic first biopsy — discuss with pathology and ordering team; repeat biopsy targeting viable tissue (PET-guided if available); open surgical biopsy for critical cases where adequate tissue is required
- Significant post-procedural bleeding — urgent CT for characterization; angiography and embolization for active arterial source
- Fracture instability after biopsy of a lytic lesion — urgent orthopedic surgery consultation; prophylactic fixation may be required
Osteomyelitis — Biopsy Yield and Clinical Utility
The diagnostic utility of image-guided bone biopsy differs substantially between vertebral and non-vertebral osteomyelitis. Understanding the expected yield and likelihood of management impact is essential before proceeding — particularly when the clinical team has already started empiric antibiotics or obtained positive blood cultures.
Vertebral Osteomyelitis-Discitis (Spondylodiscitis)
In a multicenter retrospective study of 310 image-guided biopsies for suspected vertebral osteomyelitis-discitis, the true-positive culture yield was 34%, with management affected in 36% of all cases and 78% of culture-positive cases (Malik et al., AJNR 2025). Despite modest yield, biopsy meaningfully impacts management — particularly through antibiotic tailoring when an organism is identified.
| Variable | Finding |
|---|---|
| Overall true-positive culture yield | 34% (104/310) |
| Management change — all biopsies | 36% |
| Management change — culture positive | 78% |
| Management change — culture negative | 16% (stopping or deferring antibiotics; alternate diagnosis) |
| Disc + bone aspiration vs. core only | 42% vs. 29% yield (p=0.002) — aspiration significantly improves yield |
| Disc sampling vs. bone only | 36% vs. 8% yield (p=0.006) — always include disc when accessible |
| Aspiration only | 56% yield — highest of all sampling approaches |
| Antibiotics before biopsy | No significant difference in yield (36% on abx vs. 32% off, p=0.49); biopsy yield not a reason to withhold antibiotics in unstable patients — but earlier is better |
| Prior positive blood culture | Management change lower (23%) vs. no prior culture source (41%, p=0.04) — biopsy adds less when S. aureus already identified |
IDSA guidance (2015): Defer image-guided biopsy when blood cultures are positive for S. aureus or S. lugdunensis — the organism is known and management is unlikely to change. Biopsy is indicated when microbiologic diagnosis is not established from blood or serology. In stable patients, withholding antibiotics before biopsy may improve management impact (though not yield). Core biopsy is essential even when cultures are negative — histopathology can identify alternate diagnoses (degenerative, inflammatory, malignant) that change management.
Non-Vertebral Osteomyelitis
The evidence for image-guided percutaneous needle biopsy (PNB) in non-vertebral osteomyelitis (foot, pelvis, long bones) is considerably weaker, particularly in U.S. populations. While a 2020 meta-analysis of predominantly European studies reported positive culture rates of 56–99%, U.S.-based studies consistently show much lower yields of 18–28% — potentially reflecting differences in patient population, comorbidity burden (diabetes prevalence), and institutional culture processing practices (Perry & Nacey, AJR 2022).
Critically, even when a positive culture is obtained, the management impact is limited: in one U.S. retrospective study, 48% of patients with a positive culture had no change in their empirical antibiotic regimen, and only 18% received genuinely targeted therapy. This translates to an estimated ~10% probability of both obtaining a positive culture and effecting a meaningful management change from image-guided PNB for non-vertebral osteomyelitis in the U.S. setting.
Additional technical challenges for non-vertebral osteomyelitis: Most non-vertebral cases arise from direct spread through ulceration or sinus tracts — the infection is often superficial and the biopsy trajectory must pass through non-ulcerated skin to avoid contamination, creating a new wound in a patient prone to poor healing. Wide overlying cellulitis complicates finding a clean access corridor. These technical factors contribute to higher false-negative rates compared to vertebral biopsies.
When to biopsy for non-vertebral osteomyelitis: Image-guided PNB should be reserved for cases where a positive culture result will critically change management — for example, when no organism has been identified from other sources, empiric therapy has failed, or atypical organisms (mycobacteria, fungi) are suspected. It should not be performed routinely with the expectation that positive cultures will narrow antibiotic therapy.
References
- Mankin HJ, Mankin CJ, Simon MA. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am. 1996;78(5):656–663.
- Liu PT, et al. CT-guided bone biopsy. AJR Am J Roentgenol. 2011;196(1):202–207.
- ACR-SIR Practice Parameter for Percutaneous Needle Biopsy of Bone.
- Malik DG, et al. Management Outcomes after Image-Guided Percutaneous Biopsy for Suspected Vertebral Osteomyelitis-Discitis. AJNR Am J Neuroradiol. 2025;46(7):1478–1485.
- Perry MT, Nacey NC. Bone Biopsy in Suspected Nonvertebral Osteomyelitis: Counterpoint — Limited Yield and Clinical Utility of Image-Guided Percutaneous Needle Biopsy. AJR Am J Roentgenol. 2022;219:197–198.
- Berbari EF, et al. 2015 IDSA Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clin Infect Dis. 2015;61:e26–e46.